FULL TEXT LINKS



Review > Prostaglandins Other Lipid Mediat. 2021 Dec;157:106587.

doi: 10.1016/j.prostaglandins.2021.106587. Epub 2021 Sep 10.

Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders

Seyed Mehrad Razavi¹, Danial Khayatan¹, Zahra Najafi Arab¹, Saeideh Momtaz², Kimia Zare³, Razieh Mohammad Jafari⁴, Ahmad Reza Dehpour⁵, Amir Hossein Abdolghaffari⁶

Affiliations PMID: 34517113 DOI: 10.1016/j.prostaglandins.2021.106587

Abstract

Neurological disorders result in disability and morbidity. Neuroinflammation is a key factor involved in progression or resolution of a series of neurological disorders like Huntington disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), Spinal Cord Injury (SCI), and Seizure. Thereby, antiinflammatory drugs have been developed to improve the neurodegenerative impairments. Licofelone is an approved osteoarthritis drug that inhibits both the COX (cyclooxygenase) and 5-LOX (lipoxygenase) pathways. Licofelone has pain-relieving and anti-inflammatory effects and it was shown to have neuroprotective properties in the central nervous system, which is implicated in its regulatory effect on the COX/5-LOX pathway, inflammatory cytokines, and immune responses. In this study, we briefly review the various features of neurological disorders and the function of COX/LOX in their flare up and current pharmacological products for their management. Moreover, this review attempts to summarize potential therapeutics that target the immune responses within the central nervous systems will be crucial to demonstrate the possible efficacy of Licofelone in neurological disorders.

Keywords: COX/5-LOX pathway; Inflammatory cytokines; Licofelone; Neuroinflammation; Neurological disorders.

Copyright © 2021. Published by Elsevier Inc.

Related information

MedGen PubChem Compound (MeSH Keyword)

LinkOut - more resources

Full Text Sources Elsevier Science

Medical Genetic Alliance MedlinePlus Health Information